Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature.

Abstract

After reports of the successful use of mithramycin and hydroxyurea in the myeloid blast phase of chronic granulocytic leukemia, we treated nine patients according to the protocol devised by Koller and Miller (1986). There were no complete responses, but one patient had a partial response with a transient return to the chronic phase. Of the remaining eight patients, two experienced lessening of bone pains, and one a reduction in spleen size, but without hematological improvement. The regimen was associated with significant toxicity, and no overall survival advantage. We present a review of published data regarding the use of mithramycin in chronic granulocytic leukemia which supports the results in our series. The combination of mithramycin and hydroxyurea is largely ineffective in the blast phase of chronic granulocytic leukemia, but may be of value in the accelerated phase.

• Authors: P R Johnson, J A Yin, M N Narayanan, C G Geary, E M Love, K I Cinkotai
• Journal: Hematological oncology (Hematol Oncol) 1991 Jan-Feb Vol. 9 Issue 1 Pg. 9-15 ISSN: 0278-0232 [Print] England
• PMID: 1828453 (Publication Type: Clinical Trial, Journal Article, Review)

Chemical References

• Plicamycin
• Hydroxyurea

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Blast Crisis (drug therapy)
• Humans
• Hydroxyurea (administration & dosage, therapeutic use)
• Leukemia, Myeloid, Acute (drug therapy, pathology)
• Middle Aged
• Plicamycin (administration & dosage, adverse effects, therapeutic use)